IN THE UNANED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

FEB 2 0 2007

MITRANI BO

Serial No.:

10/009,520

Filed:

May 3, 2002

For:

METHOD OF INDUCING ANGIOGENESIS

BY MICRO-ORGANS

Examiner:

SHEN, WU CHENG WINSTON

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1632

Attorney

Docket: 01/22858

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

02/22/2007 FMETEKI1 00000002 501407

10009520

01 FC:1806

180.00 DA

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: February 5, 2007

3

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Application Number 10/009,520 SUPPLEMENTAL INFORMATION Filing Date May 3, 2002 First Named Inventor **DISCLOSURE** Eduardo N. MITRANI STATEMENT BY APPLICANT Art Unit 1632 Examiner Name SHEN, Wu Cheng Winston (use as many sheets as necessary) Attorney Docket Number of 01/22858 Sheet **U.S. PATENT DOCUMENTS** Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where Applicant of Cited Document Initials* No. MM-DD-YYYY Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (if known)} US-2002/0154114 10-24-2002 Christensen et al. US-6,071,284 06-6-2000 2 Fox


	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. 1	Foreign Patent Documents	Publication Date MM-DD-YYYY		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)		Applicant of Cited Document	or Relevant Figures Appear	Ļ					
	ļ						\vdash				
	ļ										
							\vdash				
Examiner		1			Date	1					
Signature					Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperw	ork Reduction	Ac 4,1995, no persons a required to respond to a collection	on of information unless it contains a	valid OMB control number.					
	Sub	estitute is COMMAND OPTO	Complete if Known						
	Jul	ostitute is control of to	Application Number	10/009,520					
SUP	PLEM	ENTAL INFORMATION	Filing Date	May 3, 2002					
DISCLOSURE			First Named Inventor	Eduardo N. MITRANI					
			Group Art Unit	1632					
STATEMENT BY APPLICANT			Examiner Name	SHEN, Wu Cheng Winston					
	(use as	s many sheets as necessary)							
Sheet	2	Of 2	Attorney Docket Number	01/22858					
		OTHER PRIOR ART – NON PAT							
Examiner	Cite	Include name of the author (in CAPITAL LETTE							
Initials	No.1	item (book, magazine, journal, serial symposium	me-issue number(s),	T^2					
	3	publisher, city and/or country where published. Pelton et al. "Expression of Transforming Growth Factor Beta 2 RNA During Murine							
	3	Embryogensis", Development, 106(4): 759-767, 1989. Abstract.							
	4	Parrish et al. "Minireview: Precision-Cut		nc in					
	4								
	5	Pharmacology and Toxicology", Life Sciences, 57(21): 1887-1901, 1995. Mullins et al. "Transgenesis in the Rat and Larger Mammals", Journal of Clinical							
	3	d Larger Mammais, Journ	iai oi Ciinicai						
	1	Investigation, 97(7): 1557-1560, 1996.							
	6	Ledley "Pharmaceutical Approach to Somatic Gene Therapy", Pharmaceutical							
	7	Research, 13(11): 1595-1614, 1996.							
	'	Inverardi et al. "Cell Transplantation", Transplantation Biology: Cellular and							
	8	Molecular Aspects, Chap. 56: 679-687, 1996.							
	8	Wang et al. "Transgenic Studies With Keratin Promoter-Driven Growth Hormone Transgene: Prospects for Gene Therapy", Proc. Natl. Acad. Sci. USA, 94: 219-226,							
		1997.	Proc. Nati. Acad. Sci. US	A, 94: 219-220,					
-	9	Sharkawy et al. "Engineering the Tissue V	Which Engangulates Cuba	tanaaya Implanta					
	9	I. Diffusion Properties", Journal of Biome							
		1997.	edicine & Material Researc	311, 37. 401-412,					
	10		livery in A Human Ganatic	Skin Disassa"					
	10	Choate et al. "Direct Cutaneous Gene Delivery in A Human Genetic Skin Disease", Human Gene Therapy, 8: 1659-1665, 1997.							
	11	Hortelano et al. "Delivery of Human Fact		lated					
	111								
		Recombinant Myoblasts: A Novel Approach Towards Allogeneic Gene Therapy of Hemophilia B", Blood, 87(12): 5095-5103, 1996.							
		Tiemophina B , Blood, 87(12): 3093-310	3, 1990.						
		-							
	1								
	+								
	+								
					•				
	+				_				
				-					
	 			-					

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.